|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005821,
umls-concept:C0009491,
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0030705,
umls-concept:C0522523,
umls-concept:C0851827,
umls-concept:C1510438,
umls-concept:C1522318,
umls-concept:C1579762,
umls-concept:C1701901,
umls-concept:C1948041
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2003-2-21
|
|
pubmed:abstractText |
The best method for measuring the degree of platelet inhibition with glycoprotein (GP) IIb-IIIa antagonists during percutaneous coronary intervention (PCI) and the optimal degree of periprocedural inhibition is uncertain. Low molecular weight heparins have been reported to cause less platelet activation than unfractionated heparin. Therefore, compared with unfractionated heparin (UHF), a low molecular weight heparin could enhance measured platelet inhibition. In this study, we compared 3 methods of measuring platelet inhibition and investigated the effects of half doses of abciximab in combination with either UFH or the low molecular weight heparin dalteparin in patients undergoing PCI with planned abciximab administration.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1097-6744
|
|
pubmed:author |
pubmed-author:BarnardMarc RMR,
pubmed-author:BroderickThomas MTM,
pubmed-author:FoxMarsha LML,
pubmed-author:FrelingerA LAL3rd,
pubmed-author:FurmanMark IMI,
pubmed-author:HowardWendy LWL,
pubmed-author:KereiakesDean JDJ,
pubmed-author:KruegerLori ALA,
pubmed-author:MichelsonAlan DAD,
pubmed-author:MuellerMichele NMN,
pubmed-author:SchneiderJohn FJF
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
145
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
e6
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12595861-Angina, Unstable,
pubmed-meshheading:12595861-Angioplasty, Balloon, Coronary,
pubmed-meshheading:12595861-Antibodies, Monoclonal,
pubmed-meshheading:12595861-Anticoagulants,
pubmed-meshheading:12595861-Dalteparin,
pubmed-meshheading:12595861-Female,
pubmed-meshheading:12595861-Heparin,
pubmed-meshheading:12595861-Humans,
pubmed-meshheading:12595861-Immunoglobulin Fab Fragments,
pubmed-meshheading:12595861-Infusions, Intravenous,
pubmed-meshheading:12595861-Male,
pubmed-meshheading:12595861-Middle Aged,
pubmed-meshheading:12595861-Platelet Aggregation,
pubmed-meshheading:12595861-Platelet Aggregation Inhibitors,
pubmed-meshheading:12595861-Platelet Function Tests,
pubmed-meshheading:12595861-Platelet Glycoprotein GPIIb-IIIa Complex
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
|
|
pubmed:affiliation |
Center for Platelet Function Studies and Division of Cardiovascular Medicine, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA. mark.furman@umassmed.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
